KN-93

• UNSPSC Description:

  KN-93 is a cell-permeable, reversible and competitive inhibitor calmodulin-dependent kinase type II (CaMKII) with a Ki of 370 nM.

• Target Antigen:

  Autophagy; CaMK

• Type:

  Reference compound

• Related Pathways:

  Autophagy;Neuronal Signaling

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/KN-93.html

• Solubility:

  DMSO : 50 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)

• Smiles:

  O=S(C1=CC=C(OC)C=C1)(N(C2=CC=CC=C2CN(C/C=C/C3=CC=C(Cl)C=C3)C)CCO)=O

• Molecular Weight:

  501.04

• References & Citations:

  [1]Tombes RM, et al. G1 cell cycle arrest and apoptosis are induced in NIH 3T3 cells by KN-93, an inhibitor of CaMK (the multifunctional Ca2+/CaM kinase). Cell Growth Differ. 1995 Sep;6(9):1063-70.|[2]Mamiya N, et al. Inhibition of acid secretion in gastric parietal cells by the Ca2+/calmodulin-dependent protein kinase II inhibitorKN-93. Biochem Biophys Res Commun. 1993 Sep 15;195(2):608-15.|[3]Anderson ME, et al. KN-93, an inhibitor of multifunctional Ca++/calmodulin-dependent protein kinase, decreases early afterdepolarizations in rabbit heart. J Pharmacol Exp Ther. 1998 Dec;287(3):996-1006.|[4]Li J, et al. Curcumin Attenuates Retinal Vascular Leakage by Inhibiting Calcium/Calmodulin-Dependent Protein Kinase II Activity in Streptozotocin-Induced Diabetes. Cell Physiol Biochem. 2016;39(3):1196-208.Acta Pharmacol Sin. 2024 Aug 16.|Acta Pharmacol Sin. 2020 Feb;41(2):218-228. |Adv Funct Mater. 2024 Sep 02.|Ann Transl Med. 2020 Mar;8(5):219.|Arch Toxicol. 2019 Jun;93(6):1697-1712. |Biochem Biophys Res Commun. 2022 Apr 20;615:136-142.|Biochem Biophys Res Commun. 2022 Jun 25;610:170-175.|Biochem Pharmacol. 2021 Aug 9;114722.|Brain Res Bull. 2020 May;158:66-76.|Brain Res. 2023 Nov 2:148665.|Cancer Med. 2024 Nov;13(21):e70286.|Cell Calcium. 2021 Oct 5;100:102483.|Cell Cycle. 2019 Nov;18(21):2986-2997.|Cell Death Dis. 2021 May 18;12(6):504.|Cell Death Discov. 2024 Mar 26;10(1):153.|Cell Mol Life Sci. 2022 Dec 1;79(12):613.|Cell Signal. 2022 Dec 21;103:110569.|Cell Syst. 2018 Apr 25;6(4):424-443.e7.|Cell. 2022 Jun 23;185(13):2354-2369.e17.|Cell. 2024 Jun 20;187(13):3409-3426.e24.|Chin Med J. 2024 Sep 3.|Diabetes. 2018 Sep;67(9):1748-1760.|Diabetol Metab Syndr. 2023 Oct 28;15(1):217.|EMBO Mol Med. 2022 Dec 13;e16373.|Eur J Pharmacol. 2024 Mar 11:176483.|Evid-Based Compl Alt. Dec 12.|Exp Cell Res. 2018 Mar 15;364(2):198-207. |FASEB J. 2019 Dec;33(12):13644-13659.|FEBS Lett. 2022 Jun 18.|Front Genet. 2022 Aug 4;13:959360.|Front Pharmacol. 2018 Apr 12;9:362. |Front Pharmacol. 2022, 13: 5319.|Harvard Medical School LINCS LIBRARY|J Agric Food Chem. 2019 Dec 26;67(51):14074-14085.|J Cardiovasc Transl Res. 2024 Jan 16.|J Cell Biochem. 2019 Aug;120(8):13095-13106.|J Cell Mol Med. 2020 Aug;24(16):9287-9299.|J Endocrinol. 2018 Mar;236(3):151-165. |J Ethnopharmacol. 2023 Aug 9;117016.|J Mol Cell Cardiol. 2021 Nov 10;S0022-2828(21)00210-8.|J Mol Histol. 2021 Apr 26.|J Neurosci. 2022 Jun 27;JN-RM-1989-21.|J Pineal Res. 2024 Aug;76(5):e12987.|Life Sci. 2020 Apr 1;246:117419.|Mol Cell Biol. 2024;44(4):149-163.|Neuropsychiatr Dis Treat. 2024 Sep 11:20:1693-1710.|Neurosci Lett. 2021 Feb 1;135699.|Neuroscience. 4 March 2022.|Oncol Rep. 2019 Jun;41(6):3413-3423. |Oxid Med Cell Longev. 2019 Dec 7;2019:2193019.|Oxid Med Cell Longev. 2021 Mar 30.|Phytomedicine. 2024 Aug 22:134:155958.|Redox Biol. October 2021, 102115.|Research Square Preprint. 2021 Oct.|Sci Total Environ. 2020 Feb 10;703:134702.|SSRN. 2024 Apr 4.|Toxicology. 2023 Apr 17, 153514.|Transl Stroke Res. 2023 Feb 13.|World J Diabetes. 2022 Apr 15;13(4):338-357.|Commun Biol. 2022 Jul 28;5(1):750.|Environ Res. 2024 Aug 15:255:119210.|Front Med. 2023 Feb 4.|Nat Commun. 2022 Jul 22;13(1):4255.|Nat Metab. 2020 Sep;2(9):918-933.|Sci Rep. 2023 Dec 7;13(1):21712.

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  139298-40-1